Join this webcast to learn formulation strategies to eliminate cold chain requirements for proteins using dry powders manufactured by spray drying. Inhaled delivery of biotherapeutic active ...
A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteria, scientists report. Community-acquired pneumonia, a type of lung inflammation contracted outside of a ...
Dry Powder Inhalers (DPIs) are employed to supply a safe dose of Active Pharmaceutical Ingredient (API) to the deep lung. Image Credit: Freeman Technology An excipient transports the delicate ...
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "INBRIJA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...
Wednesday, November 16, 2022 at 11 am ET | 8 am PT | 4 pm GMT | 5 pm CET This webinar will discuss challenges and key considerations for spray-dried formulations for inhalation, along with a review of ...
The FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 10-3 to recommend approval of Boehringer Ingelheim's mist formulation of its dry-powder inhalable treatment for chronic obstructive ...
Detailed particle characterization, including shape and size analysis and chemical identification, enables thorough understanding of drug formulations. This level of knowledge creates confidence and ...
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...
According to Future Market Insights, the global Dry Powder Inhaler Market is slated to exhibit a CAGR of nearly 4.6% during the forecast period (2021-2031), in terms of volume. Over 4000,000 Mn units ...
Climbing to New Heights: The Global Dry Powder Inhaler Industry Anticipates Impressive 4.6% CAGR Growth from 2021 to 2031, Envisioning a Market Valued at Approximately US$ 18.9 Billion in 2021. Future ...
The Food and Drug Administration (FDA) has approved Teva's ProAir RespiClick (albuterol sulfate inhalation powder), the first breath-actuated dry-powder inhaler approved for acute asthma symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback